Steven Kelley, MD
Interventional Cardiology · Baton Rouge, LANPI 1922069103
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $79,375 of the $116,484 with a category attached, or 68.1%. Edwards Lifesciences accounts for 93.9% of it on its own, with 27 other manufacturers making up the rest. Among interventional cardiology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 317 payments — averaging $367.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$109K
- Abbott$2K
- Medtronic$1K
- Shockwave Medical, Inc$703
- Boston Scientific$615
- Novartis$458
- plus $2K from 22 others
What the payments were for
- Consulting fees$79,37568%
- Speaking & faculty fees$8,4007%
- Travel & lodging$19,10216%
- Food & beverage$9,6088%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 138 | $109,381 |
| Abbott | 19 | $1,946 |
| Medtronic | 17 | $1,293 |
| Shockwave Medical, Inc | 11 | $703 |
| Boston Scientific | 9 | $615 |
| Novartis | 33 | $458 |
| Abiomed | 11 | $420 |
| Merck | 10 | $211 |
| Amgen | 16 | $206 |
| Angiodynamics, Inc. | 2 | $192 |
| Irhythm Technologies, Inc. | 9 | $148 |
| Johnson & Johnson | 8 | $132 |
| Kestra Medical Technology Services, Inc. | 4 | $116 |
| Alnylam Pharmaceuticals Inc. | 3 | $95 |
| AstraZeneca | 5 | $85 |
| Pfizer | 4 | $67 |
| E.r. Squibb & Sons, L.L.C. | 3 | $53 |
| Baxter Healthcare | 1 | $49 |
| Silk Road Medical, Inc. | 1 | $47 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $39 |
| Itamar Medical Inc | 1 | $37 |
| Cardiovascular Systems Inc. | 2 | $34 |
| Novo Nordisk | 2 | $33 |
| Impulse Dynamics (USA) Inc. | 1 | $28 |
| Cardiva Medical, Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$86,983
- SAPIEN 3 Ultra RESILIA$2,787
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$1,993
- Mitra Clip system$1,238
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$561
- CoreValve Evolut$289
- 3F$283
- Auryon Laser System 100-120 Vac$165
- General - Balloon Catheters$142
- COREVALVE EVOLUT R$141
- Impella$140
- Fortify Assura, Ellipse ICD$112
How this compares
$116,484 in reported general payments places this provider in the 90th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 469 | $356,343 |
| EntrestoSacubitril/Valsartan | 119 | $115,751 |
| XareltoRivaroxaban | 105 | $90,303 |
| Repatha SureclickEvolocumab | 24 | $17,297 |
| BrilintaTicagrelor | 30 | $14,285 |
| FarxigaDapagliflozin Propanediol | 22 | $11,136 |
| Metoprolol Succinate | 718 | $7,574 |
| ClopidogrelClopidogrel Bisulfate | 609 | $5,991 |
| Hydralazine Hcl | 390 | $5,578 |
| Valsartan | 158 | $4,775 |
| Atorvastatin Calcium | 420 | $4,127 |
| Clonidine | 32 | $4,079 |
| Amlodipine Besylate | 617 | $2,987 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 11 | $2,887 |
| Verapamil Er PmVerapamil Hcl | 13 | $2,870 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $67 | $356,343469 claims |
| NovartisEntresto | $458 | $115,751119 claims |
| Johnson & JohnsonXarelto | $132 | $90,303105 claims |
| AstraZenecaBrilinta, Farxiga | $85 | $25,42152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Baton Rouge
- Denzil MoraesBaton Rouge$901K
- Jorge CastellanosBaton Rouge$185K
- Venkata GadiBaton Rouge$117K
- Garland GreenBaton Rouge$37K
- Harold HelmkeBaton Rouge$32K
- Lance LamotteBaton Rouge$24K
- Daniel FontenotBaton Rouge$16K
- Amit PatelBaton Rouge$16K
- Craig WalkerHouma$5M
- Ankur LodhaLafayette$640K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.